好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Dysfunction of the Default Mode Network in Early Parkinson's Disease: A Resting State fMRI Study
Movement Disorders
P06 - (-)
081
BACKGROUND: PD is characterized by dopamine depletion in the nigrostriatal system. According to the basal ganglia-thalamocortical circuit model, this leads to an abnormal modulation of cortico-subcortical networks. Functional MRI (fMRI) revealed less deactivation of DMN during cognitive tasks in not-demented PD patients compared to healthy controls (HC). On the other hand, a recent study showed decreased connectivity within DMN in PD patients with dementia. RS analysis of DMN in early PD patients might reveal neural correlates of cognitive functions prior to the clinical manifestations of their impairments.
DESIGN/METHODS: We enrolled 57 early PD patients (Hoehn and Yahr stage I) without cognitive impairment (mild cognitive impairment or dementia) and 24 HC. We analyzed RS fMRI data using a model free (MELODIC) approach in FSL.
RESULTS: PD patients showed increased connectivity within the DMN structures including the superior and middle temporal gyri, hippocampi, parahippocampal cortex, precuneus, posterior, middle and anterior cingulate cortices compared to HC bilaterally (p <0.05 FWE corrected).
CONCLUSIONS: We demonstrated a dysfunction of DMN in the very early PD patients without cognitive impairment. There are two possible explanations for our findings. DMN abnormal connectivity in PD could be due to a compensatory mechanism that precedes clinically relevant cognitive impairment. Conversely, it could be secondary to a reduced thalamic outflow to the prefrontal cortex with the impairment of input/output information flows from and to this area and other DMN cortices.
Authors/Disclosures
Francesca Caso, MD (Universita' Vita Salute San Raffaele)
PRESENTER 		Dr. Caso has nothing to disclose.
No disclosure on file
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
No disclosure on file
Alexandra Tomic No disclosure on file
Iva Stankovic (Neurology Clinic, Clinical Center of Serbia, University of Belgrade) Iva Stankovic has nothing to disclose.
Elisa Canu (Ospedale San Raffaele) The institution of Elisa Canu has received research support from Italian Ministry of Health .
No disclosure on file
Vladimir S. Kostic, MD, PhD (Institute of Neurology CCS) Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. An immediate family member of Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkaloid. The institution of Dr. Kostic has received research support from Ministry of 好色先生, Science and Technological Development of Serbia.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.